KR101416078B1 - 변형된 인간화 항­인터루킨­１８ 항체 - Google Patents

변형된 인간화 항­인터루킨­１８ 항체 Download PDF

Info

Publication number
KR101416078B1
KR101416078B1 KR1020087031233A KR20087031233A KR101416078B1 KR 101416078 B1 KR101416078 B1 KR 101416078B1 KR 1020087031233 A KR1020087031233 A KR 1020087031233A KR 20087031233 A KR20087031233 A KR 20087031233A KR 101416078 B1 KR101416078 B1 KR 101416078B1
Authority
KR
South Korea
Prior art keywords
ser
antibody
thr
val
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087031233A
Other languages
English (en)
Korean (ko)
Other versions
KR20090023625A (ko
Inventor
조나단 헨리 엘리스
볼커 게르마쉐우스키
폴 앤드류 함블린
이안 키르비
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101416078(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0610438A external-priority patent/GB0610438D0/en
Priority claimed from GB0611046A external-priority patent/GB0611046D0/en
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20090023625A publication Critical patent/KR20090023625A/ko
Application granted granted Critical
Publication of KR101416078B1 publication Critical patent/KR101416078B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
KR1020087031233A 2006-05-25 2007-05-23 변형된 인간화 항­인터루킨­１８ 항체 Expired - Fee Related KR101416078B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0610438A GB0610438D0 (en) 2006-05-25 2006-05-25 Immunoglobulins
GB0610438.4 2006-05-25
GB0611046.4 2006-06-05
GB0611046A GB0611046D0 (en) 2006-06-05 2006-06-05 Immunoglobulins
PCT/EP2007/055029 WO2007137984A2 (en) 2006-05-25 2007-05-23 Modified humanised anti-interleukin-18 antibodies

Publications (2)

Publication Number Publication Date
KR20090023625A KR20090023625A (ko) 2009-03-05
KR101416078B1 true KR101416078B1 (ko) 2014-07-07

Family

ID=38476914

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087031233A Expired - Fee Related KR101416078B1 (ko) 2006-05-25 2007-05-23 변형된 인간화 항­인터루킨­１８ 항체

Country Status (22)

Country Link
US (5) US8133978B2 (https=)
EP (1) EP2027157B1 (https=)
JP (1) JP5420399B2 (https=)
KR (1) KR101416078B1 (https=)
AR (1) AR061115A1 (https=)
AU (1) AU2007267213B2 (https=)
BR (1) BRPI0711908B8 (https=)
CA (1) CA2652733C (https=)
CR (1) CR10468A (https=)
EA (1) EA017303B1 (https=)
ES (1) ES2514495T3 (https=)
IL (1) IL194995A0 (https=)
MA (1) MA30486B1 (https=)
MX (1) MX2008014842A (https=)
MY (1) MY157173A (https=)
NO (1) NO341921B1 (https=)
NZ (1) NZ572565A (https=)
PE (1) PE20080262A1 (https=)
SG (1) SG172625A1 (https=)
TW (1) TWI422387B (https=)
WO (1) WO2007137984A2 (https=)
ZA (1) ZA200809662B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CA2652733C (en) 2006-05-25 2016-06-21 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JP2012500242A (ja) * 2008-08-18 2012-01-05 グラクソ グループ リミテッド Ｉｌ−１８アンタゴニストを用いる自己免疫疾患の治療
MX2011001117A (es) 2008-08-27 2011-03-02 Hoffmann La Roche Metodo para cribado de anticuerpo de alta afinidad.
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
CN102482344B (zh) 2009-08-25 2014-09-17 弗·哈夫曼-拉罗切有限公司 速度因子
WO2011098424A2 (en) 2010-02-09 2011-08-18 Glaxo Group Limited Treatment of a metabolic disorder
WO2011127141A1 (en) * 2010-04-07 2011-10-13 Abbott Laboratories TNF-α BINDING PROTEINS
AR083937A1 (es) * 2010-11-23 2013-04-10 Glaxo Group Ltd Proteinas de union a antigenos
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
US20130149308A1 (en) * 2011-08-12 2013-06-13 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
ES2742413T3 (es) 2012-11-21 2020-02-14 Km Biologics Co Ltd Nuevo anticuerpo humano contra IL-18
AU2014265624B2 (en) * 2013-05-15 2019-09-12 Medimmune Limited Purification of recombinantly produced polypeptides
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
WO2017076805A1 (en) * 2015-11-02 2017-05-11 Glaxosmithkline Intellectual Property Development Limited Use of an inhibitor of il18 for treatment of acute kidney injury
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
JP2023549257A (ja) 2020-11-18 2023-11-22 ノバルティス アーゲー Ｎｌｒｃ４－ｇｏｆインフラマソーム病の処置における使用のための二特異性抗体
EP4371573A4 (en) 2021-07-13 2025-08-20 National Univ Corporation Tokai National Higher Education And Research System MEDICINAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
WO2023056193A2 (en) * 2021-09-29 2023-04-06 Chimera Bioengineering, Inc. Il-18 variants and uses thereof
AU2024314970A1 (en) 2023-06-20 2026-01-15 Apollo Ap43 Limited Anti-il-18 antibody therapy for treating atopic dermatitis
WO2025229563A1 (en) * 2024-05-03 2025-11-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating inflammatory bowel disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056771A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Corporation Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
EP0628639B1 (en) * 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
DE69230545T2 (de) 1991-08-21 2000-07-06 Novartis Ag, Basel Antikörperderivate
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
JP2952750B2 (ja) 1995-02-23 1999-09-27 株式会社林原生物化学研究所 モノクローナル抗体
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
EP2338915A3 (en) * 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
TWI335336B (https=) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
NZ520122A (en) 2000-02-21 2005-04-29 Applied Research Systems Use of IL-18 inhibitors
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
MXPA03003144A (es) * 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
AU2002224417A1 (en) 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
WO2002066063A1 (en) 2001-02-23 2002-08-29 Nippon Organon K.K. Remedies for metabolic bone diseases
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
UA78516C2 (en) 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
AU2004235595C1 (en) 2003-04-30 2009-09-24 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
HRP20110657T1 (hr) * 2004-03-30 2011-10-31 Glaxo Group Limited Imunoglobulin koji se veže na osm
GB0425556D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
US20080317710A1 (en) 2006-02-22 2008-12-25 University Of Zurich Methods For Treating Autoimmune or Demyelinating Diseases
CA2652733C (en) 2006-05-25 2016-06-21 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
JP2012500242A (ja) 2008-08-18 2012-01-05 グラクソ グループ リミテッド Ｉｌ−１８アンタゴニストを用いる自己免疫疾患の治療

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056771A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Corporation Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders

Also Published As

Publication number Publication date
WO2007137984A2 (en) 2007-12-06
AU2007267213B2 (en) 2012-03-29
EP2027157B1 (en) 2014-08-06
NO20084650L (no) 2008-12-19
NO341921B1 (no) 2018-02-19
NZ572565A (en) 2011-04-29
TW200808350A (en) 2008-02-16
AU2007267213A1 (en) 2007-12-06
US9499617B2 (en) 2016-11-22
CA2652733A1 (en) 2007-12-06
CA2652733C (en) 2016-06-21
BRPI0711908B1 (pt) 2020-08-04
JP2009537608A (ja) 2009-10-29
US20070292432A1 (en) 2007-12-20
IL194995A0 (en) 2011-08-01
US20140105894A1 (en) 2014-04-17
BRPI0711908B8 (pt) 2021-05-25
TWI422387B (zh) 2014-01-11
KR20090023625A (ko) 2009-03-05
ZA200809662B (en) 2014-05-28
US10703814B2 (en) 2020-07-07
US20170029497A1 (en) 2017-02-02
CR10468A (es) 2009-01-09
US20120100137A1 (en) 2012-04-26
MA30486B1 (fr) 2009-06-01
BRPI0711908A2 (pt) 2012-01-03
JP5420399B2 (ja) 2014-02-19
US20190031753A1 (en) 2019-01-31
EA017303B1 (ru) 2012-11-30
MY157173A (en) 2016-05-13
SG172625A1 (en) 2011-07-28
US8133978B2 (en) 2012-03-13
EA200802182A1 (ru) 2009-06-30
MX2008014842A (es) 2009-02-17
US8637018B2 (en) 2014-01-28
AR061115A1 (es) 2008-08-06
PE20080262A1 (es) 2008-04-30
EP2027157A2 (en) 2009-02-25
ES2514495T3 (es) 2014-10-28
WO2007137984A3 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
KR101416078B1 (ko) 변형된 인간화 항­인터루킨­１８ 항체
JP7538721B2 (ja) 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用
AU2010201689B2 (en) IL-17 antagonistic antibodies
JP3978338B2 (ja) ヒトＩＬ−１βに対する抗体
KR101603001B1 (ko) Il-18r1에 대한 항체 및 그의 용도
CN101889026A (zh) 免疫球蛋白
JP2012531885A (ja) Ｉｌ６免疫治療剤
TWI504609B (zh) 抗原結合蛋白質
CN113651888A (zh) Il-11的抗体及其应用
CN101454343B (zh) 修饰的人源化的抗-干扰素-18抗体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170629

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200702

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200702

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000